The effects of inadequate preparation quality for colonoscopy Eric Sherer and Michael Catlin August 20 th, 2010 HSR&D Work-in-Progress 1.

Slides:



Advertisements
Similar presentations
Implementing NICE guidance
Advertisements

Colorectal Cancer Screening and Surveillance FDA Advisory Committee March, 2002 David Lieberman MD Chief, Division of Gastroenterology Oregon Health Sciences.
Exploring uncertainty in cost effectiveness analysis NICE International and HITAP copyright © 2013 Francis Ruiz NICE International (acknowledgements to:
EQUIP Training session 1
Bowel Preparation Regimens Danielle Goodrich, MSIV University of Maryland School of Medicine.
1 Sixty-Four-Slice Computed Tomography of the Coronary Arteries: Cost-Effectiveness Analysis of Patients Presenting to the ED with Low Risk Chest Pain.
Surveillance colonoscopy after polypectomy – how frequent? Dr Chu Ming Leong Tuen Mun Hospital 1.
Screening for Colorectal Cancer Cancer Symposium: Measuring the Benefits of Screening and Treatment October 2007.
“Personality, Socioeconomic Status, and All-Cause Mortality in the United States” - Chapman BP et al. Journal Club 02/24/11.
CCE 4: Bridging Clinical Expertise Using Predictive Computational Cancer Models CRC screening and follow-up – Semi-mechanistic model of CRC development.
DR Jameel Tariq Miro.  Lifetime incidence 5%  90% of cases occur after age 50  One-third of patients with colorectal cancer die from the disease 
Biostatistics ~ Types of Studies. Research classifications Observational vs. Experimental Observational – researcher collects info on attributes or measurements.
CT COLONOSCOPY. Turki Alhazmi,MB.CHB, FRCPC, dABR Interventional Radiology-Body MRI Ass. Prof. Faculty of Medicine Umm Al Qura University Makkah-Saudi.
Statistics By Z S Chaudry. Why do I need to know about statistics ? Tested in AKT To understand Journal articles and research papers.
James Cross, MS Pharmaceutical Outcomes Research and Policy Program University of Washington Biobehavioral Cancer Fellows Day April 20, 2007 A risk-benefit.
Sample Size Determination
Joint Hospital Surgical Grand Round 19 June 2004.
Clinical Practice Screening for Colorectal Cancer David A. Lieberman, M.D. N Engl J Med Volume 361(12): September 17, 2009.
Sharp L, Tilson L, Whyte S, Ó Céilleachair A
Bowel Screening in Scotland – Current Challenges and Possible Solutions Prof. Bob Steele Ninewells Hospital, University of Dundee.
1 The Chemoprevention of Sporadic Colorectal Cancer Issues Surrounding a Benefit/Risk Analysis in Clinical Trials Mark Avigan MD CM Medical Officer Division.
Benchmarking For Colonoscopy
Multiple Choice Questions for discussion
Colonoscopic surveillance for prevention of colorectal cancer in people with ulcerative colitis, Crohn’s disease or adenomas NICE CG March 2011.
Andreas Adler Charité Medical University of Berlin, Virchow Clinic Campus Central Interdisciplinary Endoscopy Unit Narrow Band versus Conventional Endoscopic.
Colonoscopy; Surveillance Indications
Decision Analysis of Colorectal Cancer Screening Tests by Age to Begin, Age to End, and Screening Intervals: Report to the United States Preventive Services.
EPIB-591 Screening Jean-François Boivin 29 September
COMPARING YIELD AND COST OF FOBT AND FS IN AN AVERAGE RISK POPULATION: RESULTS AFTER 2 SCREENING ROUNDS N.Segnan MD, Ms Epi Center for Cancer Prevention.
“The African American Prostate Cancer Crisis in Numbers”
80% by 2018 Forum: Increasing CRC Screening Rates 80% by 2018 Forum: Increasing CRC Screening Rates Implementing a Quality Screening Navigation Program.
{ Challenges in cost-utility analysis in the critical care setting Ville Pettilä MD, PhD, A/P Helsinki University Hospital VP SFAI- veckan.
1 THE ROLE OF COVARIATES IN CLINICAL TRIALS ANALYSES Ralph B. D’Agostino, Sr., PhD Boston University FDA ODAC March 13, 2006.
Patricia Guyot1,2, Nicky J Welton1, AE Ades1
Robert E. Schoen, MD MPH Associate Professor of Medicine and Epidemiology Division of Gastroenterology University of Pittsburgh Organizing Colorectal Cancer.
Estimation of the prevalence of diagnosed diabetes from primary care and secondary care source data: comparison of record linkage with capture- recapture.
1 Lecture 6: Descriptive follow-up studies Natural history of disease and prognosis Survival analysis: Kaplan-Meier survival curves Cox proportional hazards.
Evaluating Screening Programs Dr. Jørn Olsen Epi 200B January 19, 2010.
Modeling Efforts to Inform Countries’ Screening Decisions Ann Graham Zauber, Iris Vogelaar, Marjolein van Ballegooijen, Deb Schrag, Rob Boer, Dik Habbema,
Unit 15: Screening. Unit 15 Learning Objectives: 1.Understand the role of screening in the secondary prevention of disease. 2.Recognize the characteristics.
Senior Statistician Per-Henrik Zahl, MA MD PhD
Cetuximab plus FOLFIRI in the treatment of metastatic colorectal cancer: the influence of KRAS and BRAF biomarkers on outcome: updated data from the CRYSTAL.
Conceptual Addition of Adherence to a Markov Model In the adherence-naïve model, medication adherence and associated effectiveness assumed to be trial.
Do all colorectal polyps require pathological examination? Aim To assess whether it is possible to omit the pathological examination of some polyps without.
CT Colonography vs Colonoscopy for the Detection of Advanced Neoplasia David H. Kim, M.D., Perry J. Pickhardt, M.D., Andrew J. Taylor, M.D., Winifred K.
Colorectal Cancer Screening Implementation of a public health programme An Expert Group on Colorectal Cancer Screening Cancer Society of Finland, Finnish.
Results Abstract Analysis of Prognostic Web-based Models for Stage II and III Colon Cancer: A Population-based Validation of Numeracy and Adjuvant! Online.
Breast Density: Black, White and Shades of Gray Jen Rusiecki, MD VA Pittsburgh Health System Women’s Health Fellow AMWA Hot Topic 2016.
Important questions As good or better ? Cost effective ? Overall, safer? Is it safe as a cancer operation? Can all surgeons do it? Compare to open surgery.
CT Screening for Lung Cancer vs. Smoking Cessation: A Cost-Effectiveness Analysis Pamela M. McMahon, PhD; Chung Yin Kong, PhD; Bruce E. Johnson; Milton.
Towards Global Eminence K Y U N G H E E U N I V E R S I T Y Colonoscopy Surveillance After Colorectal Cancer Resection: Recommendations of the US Multi-Society.
Quality of Colonoscopy Using an endoscopic database to measure and improve quality AAPCE Memphis- November 5, 2011 David Lieberman MD Chief, Division of.
Estimating Absolute Risk Reductions Associated with Interventions in Patients with Type 2 Diabetes Jim Mold, M.D., M.P.H. Brian Firestone, MS2.
GASTROINTESTINAL ENDOSCOPY Volume 78, No. 3 : 2013 F1 김태영
Dynamic patient position changes during colonoscope withdrawal increase adenoma detection : a randomized, crossover trial James E. East, MRCP, MD, Paul.
Is suicide predictable? Paul St John-Smith Short Courses in Psychiatry 15/10/2008.
Cancer prevention and early detection
The University of Sheffield Extrapolation methods:
Clinical process indicators
Colorectal Cancer Screening Guidelines
Background & Objectives
Definition of Cancer Screening
Jasper Vleugels PhD-student AMC
Repeat Colonoscopy Recommendations
Improving Quality Measures for Colonoscopy and CRC Prevention
Feeling Rushed? Does Late Start Time Predict Poor Quality Colonoscopy?
Reporting in CRC screening
Relative risks of clinical events for primary and secondary prevention with selected drugs Thomas A Gaziano, et al. Lancet 2006; 368:
Risks of interval colorectal cancer in a FIT-based screening program
Presentation transcript:

The effects of inadequate preparation quality for colonoscopy Eric Sherer and Michael Catlin August 20 th, 2010 HSR&D Work-in-Progress 1

Outline Background – Lengthy – Adenoma detection rates – Appendix… or stand alone??? Outcomes Methods – Random questions Compliance Costs Mortality Preliminary results ORANGE TEXT => INPUT FROM AUDIENCE 2

Background 3

Detection rates - Literature Harewood et al – 93,004 colonoscopies – Adequate vs. Inadequate – POLYPS – <10 MM Froechlich et al – 5,832 colonoscopies – Low vs. Intermediate quality – Low vs. High quality – POLYPS – <10 MM 4

Unanswered questions What about adenomas? Diminutive (<=5mm) vs. small (<10mm) adenomas? – “cannot exclude adenomas <=5mm” Adjust for individual colonoscopist Want sensitivity NOT detection rates 5

Adenoma detection rates P adequate vs. fair = 0.17 P adequate vs. poor <

Adenoma detection rates P adequate vs. fair = 0.62 P adequate vs. poor = 0.80 P adequate vs. fair = 0.28 P adequate vs. poor <

Adenoma detection rates P adequate vs. fair = 0.25 P adequate vs. poor <

Adenoma detection rates Medium adenomas (6-9mm) – Adequate vs. poor prep qualities 22% relative difference; 3.2% absolute difference – Adequate vs. fair prep qualities 13% relative difference; 1.9% absolute difference P adequate vs. fair = 0.16 P adequate vs. poor =

Adenoma detection rates Medium adenomas (6-9mm) – Adequate vs. poor prep qualities 22% relative difference; 3.2% absolute difference – Adequate vs. fair prep qualities 13% relative difference; 1.9% absolute difference 10

Surveillance colonoscopy findings 11

Outcomes Effects of inadequate preparation quality – Missed adenomas => Δ cancer 12

Recommendations after 1 st colonoscopy colonoscopy prep qualities – 1,675 (64.1%) adequate – 750 (28.7%) fair – 187 (7.1%) poor ADEQUATE PREP QUALITY FAIR PREP QUALITY POOR PREP QUALITY ADEQUATE v. FAIR FAIR v. POOR Colonoscopy finding Mean recommended follow-up (s.d.) Δ Follow-up [95% CI] Δ Follow-up [95% CI] No adenomas (10yrs) 8.01yrs (2.69) n = yrs (2.65) n = yrs (2.07) n = yrs [2.72, 3.08] 3.48yrs [3.23, 3.73] 1-2 non-advanced adenomas only (5-10yrs) 4.66yrs (1.00) n = yrs (1.48) n = yrs (1.50) n = yrs [1.10, 1.36] 1.62yrs [1.34, 1.90] 3+ non-advanced adenomas only (3yrs) 3.24yrs (1.03) n = yrs (1.21) n = yrs (0.53) n = yrs [0.77, 1.07] 1.13yrs [0.91, 1.35] any advanced adenoma2.05yrs (1.36) n = yrs (1.32) n = yrs (1.49) n = yrs [0.38, 0.76] 0.29yrs [-0.17, 0.75] 13

Effect of inadequate preparation Rex et al – 400 patients 200 public hospital 200 private hospital – Authors assumed… Perfect inadequacy Perfect compliance Procedure invariance Number of projected colonoscopies Year Ideal Preparation Private Hospital Public Hospital 0 – – – – – – – Total Increase12.9%24.1% Projected total costs Cost$213,841$239,068 Cost$220,260$267,566 Increase11.8%21.5% 14

Outcomes Effects of inadequate preparation quality – Missed adenomas => Δ cancer – Earlier recalls => Δ number of tests 15

Outcomes Primary – Patient Δ E[Quality adjusted life-year (QALY)] Δ E[colon costs] Δ lifetime CRC risk – Clinic Δ E[colonoscopies / patient / life-year] – (How many more colonoscopies are done per patient each year) Secondary – Prep quality intervention 16

Methods 17

Calculations Monte Carlo trials Select patient – Colon disease free & 50<=age<=80 r1 Select random prep quality – f (gender, BMI, prev prep quality) r2 Random colonoscopy findings – History dependent r3 Select compliance – 40% - 80% reported in literature – Independent events vs. All-or-nothing r4 Determine follow-up interval – Expected vs. distributed behavior r5 Age > 80? Age > 100? Implementation All adequate prep scenario “Normal” prep scenario Range of compliances – Independent & greedy assumptions To-do: Sensitivity analysis – Costs 18

Functions 19

Measuring patient outcomes Quality-Adjusted Life Years (QALYs) 40 years Perfect health (utility 1.0) 40 QALYs 20

Measuring patient outcomes Quality-Adjusted Life Years (QALYs) 40 years Perfect health (utility 1.0) 40 QALYs 80 years Poor health (utility 0.5) 40 QALYs 21

Measuring patient outcomes Quality-Adjusted Life Years (QALYs) 40 years Perfect health (utility 1.0) 40 QALYs 80 years Poor health (utility 0.5) 40 QALYs non-cancerous0.91 local CRC0.74 regional CRC0.50 metastatic CRC0.25 Utility of model states (Ness et al. 2000) 22

Measuring clinic costs CRC treatment Initial costs Continuing costs (Ness et al. 2000) Colonoscopies Colonoscopy Polypectomy Pathology Complications Perforation LocalRegionalMetastatic Initial$16,051 / yr$18,457 / yr$21,093 / yr Continuing$425 / yr$1,944 / yr$21,209 / yr 23

Measuring clinic costs CRC treatment Initial costs Continuing costs (Ness et al. 2000) Terminal care costs not included Colonoscopies Colonoscopy Polypectomy Pathology Complications Perforation LocalRegionalMetastatic Initial$16,051 / yr$18,457 / yr$21,093 / yr Continuing$425 / yr$1,944 / yr$21,209 / yr 24

Measuring clinic costs CRC treatment Initial costs Continuing costs Colonoscopies Colonoscopy ($614 per procedure) Polypectomy ($131 for removal of polyps) Pathology ($67 per polyp examined) (Tafazzoli et al. 2009) Complications Perforation 25

Measuring clinic costs CRC treatment Initial costs Continuing costs Colonoscopies Colonoscopy Polypectomy Pathology Complications Perforation (0.2% incidence, 0.01% mortality) (Tafazzoli et al. 2009) 26

Measuring mortality Discount each event by the probability of prior mortality. 27

Measuring mortality Discount each event by the probability of prior mortality. Patient viability with age Patient age Probability of surviving from age 50 A i = age at first colonoscopy A f = current age 28

Preliminary Results 29

Clinic outcomes E[colonoscopies / patient / life-year] 30

E[N] of surveillance colonoscopies: Independent event assumption w/ ghosts 26.8% of surveillance colonoscopies due to inadequate prep 31

Patient outcomes E[QALY / patient] E[colon costs / patient] E[CRC / patient] 32

E[QALY / patient] 33

E[colon costs / patient] 34

E[CRC / patient] 35

Secondary Outcome Effect of prep quality intervention 36

E[N] surveillance colonoscopies 100% compliance InterventionLifetime E[N] surveillance colonoscopies % due to prep quality No intervention % 10% bumped 1 level % bumped 1 level % bumped 1 level

Big Picture Overall project Objective: – “Best” time for a patient to receive colon tests Tools needed – Longitudinal predictions Test parameters – Cost-utility – Decision analysis 38 Adequate First-time (Roudebush data)2.07% Following (model) First-time colonoscopy0.68% Second-time colonoscopy0.16% Third-time colonoscopy0.02%

Thank you 39

40

41

42

Limitations Discussed in Rex et al Correlation in prep qualities Additional surveillance colonoscopies Additional Likelihood of CRC Intermediate preps, detection & recs Longitudinal adenoma prevalence Study interval bias 43